

GENOME THERAPEUTICS CORP

Form 8-K

January 09, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to**

**Section 13 or 15(d) of**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): January 9, 2004**

---

**GENOME THERAPEUTICS CORP.**

**(Exact name of registrant as specified in its charter)**

**Massachusetts**

**(State or other jurisdiction  
of incorporation)**

**0-10824**

**(Commission File Number)**

**04-2297484**

**(I.R.S. Employer  
Identification Number)**

**100 Beaver Street**

**Waltham, Massachusetts 02453**

**(Address of principal executive offices, including zip code)**

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

---

Page 1 of 4 pages.

**ITEM 5. OTHER EVENTS**

On January 9, 2004, Genome Therapeutics Corp. issued a press release announcing that Genome Therapeutics and Amgen Inc. have concluded their research collaboration focused on discovering and developing therapeutics for bone diseases, which is attached hereto as Exhibit 99.1.

**Item 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on January 9, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By:

/s/ STEVEN M. RAUSCHER

**Name: Steven M. Rauscher**

**Title: President and Chief Executive  
Officer**

Date: January 9, 2004

**EXHIBIT INDEX**

**Exhibit Number**

**Description**

99.1

Press Release issued by Genome Therapeutics Corp. on January 9, 2004.